DermTech Q4 2023 GAAP EPS $(0.560) Beats $(0.570) Estimate, Sales $3.924M Miss $4.044M Estimate
Portfolio Pulse from Benzinga Newsdesk
DermTech (NASDAQ:DMTK) reported Q4 2023 earnings with a smaller than expected loss per share of $(0.560) compared to the $(0.570) estimate but missed revenue estimates with $3.924M against the expected $4.044M. Year-over-year, sales increased by 31.06% from $2.994M.
February 29, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DermTech reported a smaller than expected Q4 2023 loss per share but missed on revenue estimates, with a significant year-over-year sales increase.
The mixed results with a better-than-expected EPS but a miss on revenue forecasts could lead to neutral short-term stock price movement. The significant year-over-year sales growth indicates underlying business strength, which might offset the negative impact of the revenue miss.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100